Biohaven (BHVN) vs Mineralys Therapeutics (MLYS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Biohaven (BHVN) has outperformed Mineralys Therapeutics (MLYS) over the past year, losing 29.9% versus a loss of 40.7%. Mineralys Therapeutics is the larger company by market cap ($2.07 billion vs $1.82 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BHVN | MLYS |
|---|---|---|
| Share price | $12.08 | $23.37 |
| Market cap | $1.82B | $2.07B |
| 1-day change | +1.26% | +4.42% |
| YTD return | +7.00% | -35.60% |
| 1-year return | -29.89% | -40.67% |
| EPS (TTM) | $-4.62 | $-4.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-738.82M | $-154.65M |
| 52-week high | $18.57 | $47.65 |
| 52-week low | $7.48 | $21.46 |
| Distance from 52-week high | -34.93% | -50.95% |
| Analyst consensus | buy | none |
| Avg. price target upside | +76.08% | +107.53% |
| Average volume | 2.63M | 1.04M |
| Shares outstanding | 151.04M | 88.41M |
| Employees | 274 | 76 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BHVN has outperformed MLYS by 10.8 percentage points over the past year.
About Biohaven
BHVN stock →Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity.
Healthcare · Biotechnology · 274 employees
About Mineralys Therapeutics
MLYS stock →Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.
Healthcare · Biotechnology · 76 employees
BHVN vs MLYS FAQ
Which is bigger, Biohaven or Mineralys Therapeutics?
Mineralys Therapeutics (MLYS) is larger, with a market capitalization of $2.07B compared with $1.82B for Biohaven (BHVN).
Which stock has performed better over the past year, BHVN or MLYS?
BHVN returned -29.89% over the past 12 months, compared with -40.67% for MLYS (price return, excluding dividends). Past performance does not predict future results.
Are Biohaven and Mineralys Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.